1/13
08:42 am
tak
Takeda Pharmaceutical (NYSE:TAK) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
Low
Report
Takeda Pharmaceutical (NYSE:TAK) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
1/9
05:18 pm
tak
Takeda Pharmaceutical (TSE:4502) Valuation Check As Shares Show Strength Over Recent Periods [Yahoo! Finance]
Low
Report
Takeda Pharmaceutical (TSE:4502) Valuation Check As Shares Show Strength Over Recent Periods [Yahoo! Finance]
1/5
07:00 am
tak
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
Low
Report
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
12/30
11:04 am
tak
Celiac Disease Market Report 2025-2035: Drivers, Challenges, Opportunities, Industry Trends and Case Studies [Yahoo! Finance]
Low
Report
Celiac Disease Market Report 2025-2035: Drivers, Challenges, Opportunities, Industry Trends and Case Studies [Yahoo! Finance]
12/29
09:47 am
tak
Blending Data and Local Knowledge To Enable Sustainable Outcomes [Yahoo! Finance]
Low
Report
Blending Data and Local Knowledge To Enable Sustainable Outcomes [Yahoo! Finance]
12/24
09:31 pm
tak
????????????????????:???????????????????????????????????????????????????2033????61?3000????????????? [CNET News]
Low
Report
????????????????????:???????????????????????????????????????????????????2033????61?3000????????????? [CNET News]
12/18
04:24 am
tak
Takeda Pharmaceutical's Potential Plaque Psoriasis Therapy Meets Endpoints in Phase 3 Studies [Yahoo! Finance]
Low
Report
Takeda Pharmaceutical's Potential Plaque Psoriasis Therapy Meets Endpoints in Phase 3 Studies [Yahoo! Finance]
12/18
03:00 am
tak
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
Medium
Report
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
12/6
09:30 am
tak
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
Low
Report
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
11/28
07:12 am
tak
American Neurology Summit 2025 Achieves Major Success With Full Attendance and High Engagement
Low
Report
American Neurology Summit 2025 Achieves Major Success With Full Attendance and High Engagement
11/25
01:57 pm
tak
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
11/18
01:21 pm
tak
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
11/12
01:30 pm
tak
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
11/8
07:05 pm
tak
Takeda Pharmaceutical (TSE:4502): Assessing Valuation After Subtle Share Price Changes [Yahoo! Finance]
Low
Report
Takeda Pharmaceutical (TSE:4502): Assessing Valuation After Subtle Share Price Changes [Yahoo! Finance]
11/7
11:00 am
tak
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
Low
Report
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
11/6
08:22 am
tak
Weave Bio Launches HAQ Manager, Extending AI-Native Regulatory Automation into Critical Review Phase [Yahoo! Finance]
Low
Report
Weave Bio Launches HAQ Manager, Extending AI-Native Regulatory Automation into Critical Review Phase [Yahoo! Finance]
11/3
07:00 am
tak
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
Low
Report
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
11/1
08:05 pm
tak
Takeda Pharmaceutical (TSE:4502) Margin Miss Reinforces Bearish Narratives After ¥250.7B One-Off Loss [Yahoo! Finance]
Low
Report
Takeda Pharmaceutical (TSE:4502) Margin Miss Reinforces Bearish Narratives After ¥250.7B One-Off Loss [Yahoo! Finance]
10/30
10:48 am
tak
Competitive Landscape of Obesity Therapeutics Market Enters High-Growth Phase, Fueled by GLP-1 Surge and Expanding Oral Treatments | DataM Intelligence [Yahoo! Finance]
Neutral
Report
Competitive Landscape of Obesity Therapeutics Market Enters High-Growth Phase, Fueled by GLP-1 Surge and Expanding Oral Treatments | DataM Intelligence [Yahoo! Finance]
10/30
03:04 am
tak
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year
Medium
Report
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year
10/27
08:35 am
tak
HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation
Low
Report
HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation
10/22
05:55 pm
tak
Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies | DelveInsight [Yahoo! Finance]
Low
Report
Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies | DelveInsight [Yahoo! Finance]
10/21
08:32 pm
tak
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors [Yahoo! Finance]
Low
Report
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors [Yahoo! Finance]
10/21
08:25 pm
tak
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
Low
Report
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors